Last reviewed · How we verify
Rituximab - CHOP
Rituximab - CHOP is a Monoclonal antibody (anti-CD20) Small molecule drug developed by The Lymphoma Academic Research Organisation. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma (in combination with CHOP chemotherapy), Diffuse large B-cell lymphoma (DLBCL).
Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, used in combination with CHOP chemotherapy to treat lymphomas.
Rituximab is used in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat conditions such as Diffuse Large B Cell Lymphoma, Primary Extranodal Lymphoma, and Non-Hodgkin's Lymphoma. The mechanism of action of Rituximab involves binding to the CD20 antigen on B cells, which is verified by ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Rituximab - CHOP |
|---|---|
| Sponsor | The Lymphoma Academic Research Organisation |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes, leading to antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis of malignant B cells. When combined with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, rituximab enhances the cytotoxic effect against B-cell lymphomas. This combination, known as R-CHOP, has become a standard treatment regimen for CD20-positive lymphomas.
Approved indications
- B-cell non-Hodgkin lymphoma (in combination with CHOP chemotherapy)
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Infusion reactions
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
- Nausea/vomiting
- Fatigue
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab - CHOP CI brief — competitive landscape report
- Rituximab - CHOP updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI
Frequently asked questions about Rituximab - CHOP
What is Rituximab - CHOP?
How does Rituximab - CHOP work?
What is Rituximab - CHOP used for?
Who makes Rituximab - CHOP?
What drug class is Rituximab - CHOP in?
What development phase is Rituximab - CHOP in?
What are the side effects of Rituximab - CHOP?
What does Rituximab - CHOP target?
Related
- Drug class: All Monoclonal antibody (anti-CD20) drugs
- Target: All drugs targeting CD20
- Manufacturer: The Lymphoma Academic Research Organisation — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for B-cell non-Hodgkin lymphoma (in combination with CHOP chemotherapy)
- Indication: Drugs for Diffuse large B-cell lymphoma (DLBCL)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing